Substance Use Tools & Resources    

This guide will explans how to choose a screening tool for Perinatal Mood and Anxiety Disorders (PMADs), provides recommendations and resources on how to administer the tools, recommends additional screening tools, presents an algorithm and response protocol, and briefly touches on establishing outside resources and referrals.

This brief describes the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model for pregnant and postpartum women with substance use disorders and how to implement and integrate SBIRT into care delivery.

This report, produced in collaboration with the Partnership to End Addiction, analyzes standards of prior authorization requirements in both public and private insurance plans.

This report, produced in collaboration with the Partnership to End Addiction, analyzes requirements for health plans to use specific criteria and assessment tools to determine medical necessity for substance use disorders.

This report, produced in collaboration with the Partnership to End Addiction, analyzes states' parity compliance reporting requirements for mental health and substance use disorder,

This report, produced in collaboration with the Partnership to End Addiction, discusses federal and state regulation and enforcement of the Parity Act with regard to network adequacy for substance use disorder and mental health services.

This guide includes best opportunities for driving improvements in opioid stewardship within their organization and community.

This toolkit provides a compelling argument for upholding generally accepted standards of care and practical tools for implementing an effective appeal strategy, including appeal letter templates and insurance claim review talking points.

Describes key considerations for implementing substance use disorder services during COVID-19, including safety precautions, ways to move all services to telehealth, reimbursement contingencies, and leadership actions

Provides an update on providing telehealth services for substance use during COVID-19 and best practices for safely managing treatment during COVID-19